Jianfeng Group Lin2016 -021 (Announcement of Letter of Intent for Limin Chemical Cooperation)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2016-021
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Prompt Announcement on Subsidiaries Signing Letter of Intent for Cooperation
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important Content Reminder:
l Transaction Brief Content: Zhejiang Jianfeng Pharmaceutical Co., Ltd., the company's holding subsidiary, recently signed a Letter of Intent for Cooperation with Zhejiang Limin Holding Co., Ltd. to cooperate with it in the pharmaceutical intermediate business.
l This transaction does not constitute a related party transaction
l This transaction does not constitute a major asset reorganization
l This is a letter of intent for cooperation, which is the basis of cooperation negotiations. There is uncertainty as to whether the cooperation can be realized.
Overview of 1. Foreign Investment
(I) Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, recently signed a "Letter of Intent for Cooperation" with Zhejiang Limin Holdings Co., Ltd. (hereinafter referred to as "Limin Holdings") to carry out cooperation in the pharmaceutical intermediate business based on the pharmaceutical intermediate business segment of the subsidiary of Limin Holdings. The two sides intend to set up a new company in Suichang County, Lishui City, Zhejiang Province, Limin Holdings intends to invest in the physical assets of the pharmaceutical intermediates sector of the following subsidiaries, and Peak Pharmaceuticals intends to contribute in cash.
(II) signed a letter of intent for cooperation, which is the basis for cooperation negotiations. Specific matters need to be further negotiated according to the results of audit, evaluation and due diligence. The formal cooperation agreement will also be reviewed through the decision-making process in accordance with the "Stock Listing Rules" and the company's "Articles of Association.
(III) The cooperation is not a connected transaction, nor does it constitute a major asset reorganization as stipulated in the Measures for the Administration of Major Asset Reorganization of Listed Companies.
Basic Information of 2. Partners
1 , Enterprise Name: Zhejiang Limin Holding Co., Ltd.
2 , Enterprise Nature: Limited Liability Company
3 , Place of Registration:
4 , Changlian Village, Yunfeng Street, Suichang County, Zhejiang Province, Date of Registration: 2016# April 11, 75
5 , main office location: Changlian Village, Yunfeng Street, Suichang County, Zhejiang Province
6 , legal representative: Li Feng
7 , registered capital: Limin Holding's registered capital is 5250 yuan, and the paid-in capital as of the announcement date is 15 million yuan.
8 , main business: industrial investment
9 , major shareholders:
Serial Number |
Shareholder Name or Name |
Contribution (RMB 10,000) |
Contribution Proportion |
1 |
li Feng |
1761.375 |
33.550 |
2 |
Lishui Lihe Investment Partnership |
177.1875 |
3.375 |
3 |
Lishui Lishun Investment Partnership |
177.1875 |
3.375% |
4 |
Lishui Lichang Investment Partnership |
177.1875 |
3.375% |
5 |
Lishui Lian Investment Partnership |
177.1875 |
3.375 |
6 |
Lishui Lizi Investment Partnership |
259.875 |
4.95% |
Another, mr. Li Feng is the managing partner of the above 2-6 partnership, accounting for 2.22 of Lishui Lihe Investment Partnership, 2.22 of Lishui Lishun Investment Partnership, 6.67 of Lishui Lichang Investment Partnership, 2.22 of Lishui Lian Investment Partnership and 40.91 of Lishui Liqi Investment Partnership.
Basic Information on 3. Cooperation Target
(I) This cooperation is to be relocated and transformed based on the pharmaceutical intermediate business segment of Zhejiang Limin Chemical Co., Ltd. (hereinafter referred to as "Limin Chemical") controlled by Limin Holdings to carry out cooperation in pharmaceutical intermediate business.
(II) Limin Chemical was established on May 29, 1998 . The current registered capital is 35 million yuan, of which: Limin Holdings accounts for 42.86 as the largest shareholder and Li Feng accounts for 15.6; The residence is Zhuangshan, Suichang County, Zhejiang Province. Mainly engaged in civil blasting equipment, chemical products and other related products. The main products of the chemical sector are: SP-80 emulsifier, 2-imidazolidinone, 1-chloroformyl-2-imidazolidinone products.
(III) As of the end of 2015 , Limin Chemical had total assets of 169.3742 million yuan, net assets of 57.3046 million yuan, operating income of 140.036 million yuan in 2015 (including operating income of chemical intermediates of about 45 million yuan) and net profit of 9.1185 million yuan. As of the end of the first quarter of 2016, Limin Chemical had total assets of 168.2613 million yuan and net assets of 58.2794 million yuan, in the first quarter of 2016, the operating income was 32.6912 million yuan (including the operating income of chemical intermediates was about 13.88 million yuan) and the net profit was 933800 yuan. The above financial data has not been audited by an accounting firm with securities qualification.
Main Contents of Letter of Intent for 4. Cooperation
On May 10, 283, 2016 , Limin Holdings (Party A) and Jianfeng Pharmaceutical (Party B) signed the Letter of Intent for Cooperation, with the main terms as follows:
(I) Cooperation ModeParty A and Party B intend to cooperate on the basis of Party A's existing pharmaceutical intermediate business sector and set up a new company in Suichang County. Party A intends to contribute the physical assets of the pharmaceutical intermediate sector and Party B intends to contribute in cash. The scope of business is mainly bulk drugs, pharmaceutical intermediates, etc. The registered capital and contribution ratio of the specific company shall be negotiated separately.
(II) Follow-up Work Arrangement
1
. Both parties jointly set up a working group to carry out preliminary certification of the project and carry out other related work.
2. Party A shall confirm the rights and assets of the physical assets to be invested, and make preliminary preparations such as audit, evaluation and due diligence. Coordinate with the local government and relevant departments to do a good job in the site selection arrangement of the cooperation project, land supply, environmental assessment approval, industrial and commercial registration, and strive for preferential tax policies and other affairs related to the cooperation project.
3, do a good job in product selection, investment budget and other preliminary feasibility study work.
(III) exclusive matters1
, unless approved in writing by party B, within 6 months after the signing of this agreement (hereinafter referred to as exclusive period), party A and any representative under its control shall not, directly or indirectly, seek to engage, negotiate, negotiate or sign any agreement or letter of intent with any third party (whether or not such agreement or letter of intent is binding on it) with respect to any matter agreed upon in this Agreement.
5. the impact of this cooperation on the company and risk tipsThis cooperation is based on the company's strategic plan to expand and strengthen the pharmaceutical business. If the cooperation can be successfully completed, on the one hand, it will establish a production base for pharmaceutical intermediate raw materials of Jianfeng Pharmaceutical, laying a foundation for the further development of the company's pharmaceutical business; on the other hand, it can also realize the extension and development of the peak pharmaceutical industry chain.
In view of the letter of intent signed this time, further negotiations are needed on the basis of audit, evaluation and due diligence. The specific cooperation mode and investment scale will also perform the deliberation procedures of the board of directors or the general meeting of shareholders in accordance with the provisions of the stock listing rules and the articles of association of the company; the site selection and environmental assessment of the project relocation and transformation also need the approval of relevant government departments. There is uncertainty about whether the cooperation can be realized. The company will disclose the follow-up progress in a timely manner according to the progress of the cooperation. Investors are kindly requested to pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
May 10, 2016
More information
Recently, it was learned from the competent department that the "ERP/MES full-process informatization" project of Jianfeng Pharmaceutical Company has been included in the list of key projects of "integration of industrialization and industrialization" in Jinhua City, and has now entered the publicity period. In order to speed up the in-depth integration of informatization and industrialization, according to the evaluation criteria in Jinhua City's "Several Opinions on Accelerating Informatization Construction" and "Jinhua City Informatization and Industrialization Integration Key Project Management Measures", 148 projects were included in 2017 Jinhua City's "Integration of Industrialization and Industrialization" key projects. The "ERP/MES Full Process Informatization" project of Jianfeng Pharmaceutical Co., Ltd. was finally included in the list after being recommended, material reviewed and expert reviewed by Jinhua Economic and Information Committee. The ERP-level subsystems of ERP/MES full-process informatization project include sales system, procurement system, MRP system, GMPQbD system, connecting UFIDA financial software and HR system. MES-level subsystems include industrial data acquisition and monitoring system, GAMP/MES system, eBPR (electronic batch production record system), cGMP quality assurance system, QC/eBTR(QC process and electronic batch inspection record system), LIMS system, etc. After the construction is completed, the visualization of drug production process and the collection and integration of industrial data will be realized. Realize the electronization of drug production process parameters, electronic batch production and inspection records; the realization of big data integration of industrial data and information will also be in line with the regulatory concept of GMP data integrity and quality traceability to the greatest extent. The establishment of a unified enterprise information platform will eliminate information islands and realize data one.
2020
07-31
The company's first-half profit record high
According to the 15th meeting of the ninth board of directors of the company on August 25, in the first half of 2017, the company achieved a net profit of 240.5357 million yuan, the highest level in half a year's history. In the first half of 2017, the company focused on the general work policy of "grasping trends, precise development, strengthening management, and improving efficiency", grasping the opportunities brought by economic structure optimization and industrial upgrading, strengthening lean production and management improvement internally, and actively exploring externally Develop new opportunities and continue to promote the "three reductions and three improvements" work. Through the joint efforts of all employees of the company, the best semi-annual performance in history has been achieved. As of the end of June 2017, the company's total assets were 4.226 billion yuan and net assets were 2.511 billion yuan; the company achieved total operating income of 1,305.9327 million yuan, an increase of 18.42 percent over the same period last year, and net profit attributable to owners of the parent company was 240.5357 million yuan, an increase of 132.11 percent over the same period last year. Earnings per share are 0.7 yuan. In the second half of the year, the company will continue to focus on the annual business plan, carry out in-depth work of "three reductions and three improvements", further do a good job in internal control, prevent business risks, and further do a good job in safety and environmental protection. we will further develop and improve the complementary relatively diversified main business structure and constantly enhance the company's core competitiveness. The 15th meeting of the 9th board of directors held on August 25 was presided over by Jiang Xiaomeng, chairman of the group company. Four proposals and reports including the 2017 semi annual report and the proposal on the change of the company's accounting policy were deliberated and passed. on the same day, the 12th meeting of the eighth board of supervisors was held,
2020
07-31
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-30
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-31
Spike Pharmaceuticals set out to explore a new sales model
Agency and Terminal Link Production and Chain Cooperation Spike Pharmaceuticals to Explore New Sales Models From August 16 to 21, the 2017 China Pharmaceutical Retail Industry Information Conference (hereinafter referred to as "Xipu Conference") with the theme of "Building a Blueprint-Market Awakening Focusing on Demand" was held in Boao, Hainan. Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and relevant leaders of Spike Health, pharmaceutical sales company and Spike Pharma pharmacy were invited to attend the event, to create a new sales model "road". This year coincides with the 10th anniversary of the Western Conference. More than 1200 mainstream chain pharmacies, more than 800 brand pharmaceutical industries, more than 100 cross-border affiliated institutions, more than 130 top domestic and foreign capital institutions, more than 60 representatives of authoritative media, and authoritative experts in the industry, with nearly 4000 people gathered in Boao. The meeting combed the context of the pharmaceutical retail industry in the past ten years, discussed the development of the industry in the new decade, and built a new blueprint for the industry. During the meeting, Huang Jinlong led the peak participants to have in-depth exchanges with the organizers of the conference and industry experts on issues such as the impact of national policies such as the brand strategy of enterprises, the role of brand enterprises in the industry, medical reform, prescription outflow, etc. on the original sales mode of pharmaceutical enterprises. He also had extensive contact with pharmaceutical counterparts and terminal chains, listened to front-line sales experience, collected relevant information on terminal chains, and collected market trends of the top 100 chains. In the past ten years, the scale of drug retail sales in China has increased from 143 billion yuan to 337.7 billion yuan, and the chain rate has increased from 35.3 percent to 49.4 percent.
2020
07-31
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-31